A Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies of Eicosapentaenoic and Docosahexaenoic Long-Chain Omega-3 Fatty Acids and Coronary Heart Disease Risk
- PMID: 28062061
- DOI: 10.1016/j.mayocp.2016.10.018
A Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies of Eicosapentaenoic and Docosahexaenoic Long-Chain Omega-3 Fatty Acids and Coronary Heart Disease Risk
Abstract
Objective: To conduct meta-analyses of randomized controlled trials (RCTs) to estimate the effect of eicosapentaenoic and docosahexaenoic acid (EPA+DHA) on coronary heart disease (CHD), and to conduct meta-analyses of prospective cohort studies to estimate the association between EPA+DHA intake and CHD risk.
Methods: A systematic literature search of Ovid/Medline, PubMed, Embase, and the Cochrane Library from January 1, 1947, to November 2, 2015, was conducted; 18 RCTs and 16 prospective cohort studies examining EPA+DHA from foods or supplements and CHD, including myocardial infarction, sudden cardiac death, coronary death, and angina, were identified. Random-effects meta-analysis models were used to generate summary relative risk estimates (SRREs) and 95% CIs. Heterogeneity was examined in subgroup and sensitivity analyses and by meta-regression. Dose-response was evaluated in stratified dose or intake analyses. Publication bias assessments were performed.
Results: Among RCTs, there was a nonstatistically significant reduction in CHD risk with EPA+DHA provision (SRRE=0.94; 95% CI, 0.85-1.05). Subgroup analyses of data from RCTs indicated a statistically significant CHD risk reduction with EPA+DHA provision among higher-risk populations, including participants with elevated triglyceride levels (SRRE=0.84; 95% CI, 0.72-0.98) and elevated low-density lipoprotein cholesterol (SRRE=0.86; 95% CI, 0.76-0.98). Meta-analysis of data from prospective cohort studies resulted in a statistically significant SRRE of 0.82 (95% CI, 0.74-0.92) for higher intakes of EPA+DHA and risk of any CHD event.
Conclusion: Results indicate that EPA+DHA may be associated with reducing CHD risk, with a greater benefit observed among higher-risk populations in RCTs.
Copyright © 2016 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.
Comment in
-
Prescribing More Stringent Design of Randomized Clinical Trials of Omega-3 Polyunsaturated Fatty Acids.Mayo Clin Proc. 2017 Jun;92(6):1005-1006. doi: 10.1016/j.mayocp.2017.03.019. Mayo Clin Proc. 2017. PMID: 28578776 No abstract available.
-
In Reply I-Prescribing More Stringent Design of Randomized Clinical Trials of Omega-3 Polyunsaturated Fatty Acids.Mayo Clin Proc. 2017 Jun;92(6):1006-1007. doi: 10.1016/j.mayocp.2017.04.003. Mayo Clin Proc. 2017. PMID: 28578777 No abstract available.
Similar articles
-
Intake of total omega-3 fatty acids, eicosapentaenoic acid and docosahexaenoic acid and risk of coronary heart disease in the Spanish EPIC cohort study.Nutr Metab Cardiovasc Dis. 2014 Mar;24(3):321-7. doi: 10.1016/j.numecd.2013.08.011. Epub 2013 Dec 20. Nutr Metab Cardiovasc Dis. 2014. PMID: 24360762
-
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.Cochrane Database Syst Rev. 2018 Nov 30;11(11):CD003177. doi: 10.1002/14651858.CD003177.pub4. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2020 Feb 29;3:CD003177. doi: 10.1002/14651858.CD003177.pub5. PMID: 30521670 Free PMC article. Updated.
-
Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials.Am J Hypertens. 2014 Jul;27(7):885-96. doi: 10.1093/ajh/hpu024. Epub 2014 Mar 6. Am J Hypertens. 2014. PMID: 24610882 Free PMC article.
-
EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials.J Am Coll Nutr. 2009 Oct;28(5):525-42. doi: 10.1080/07315724.2009.10719785. J Am Coll Nutr. 2009. PMID: 20439549 Review.
-
Eicosapentaenoic Acid Versus Docosahexaenoic Acid as Options for Vascular Risk Prevention: A Fish Story.Am J Ther. 2016 May-Jun;23(3):e905-10. doi: 10.1097/MJT.0000000000000165. Am J Ther. 2016. PMID: 25828517 Review.
Cited by
-
Omega-3 Polyunsaturated Fatty Acids Supplements and Cardiovascular Disease Outcome: A Systematic Review and Meta-Analysis on Randomized Controlled Trials.Rev Cardiovasc Med. 2023 Jan 12;24(1):24. doi: 10.31083/j.rcm2401024. eCollection 2023 Jan. Rev Cardiovasc Med. 2023. PMID: 39076869 Free PMC article.
-
Omega-3 (n-3) Fatty Acid-Statin Interaction: Evidence for a Novel Therapeutic Strategy for Atherosclerotic Cardiovascular Disease.Nutrients. 2024 Mar 27;16(7):962. doi: 10.3390/nu16070962. Nutrients. 2024. PMID: 38612996 Free PMC article. Review.
-
Evaluating agreement between evidence from randomised controlled trials and cohort studies in nutrition: a meta-research replication study.Eur J Epidemiol. 2024 Apr;39(4):363-378. doi: 10.1007/s10654-023-01058-5. Epub 2024 Jan 4. Eur J Epidemiol. 2024. PMID: 38177572 Free PMC article.
-
Association of Fish Oil Supplementation with Risk of Coronary Heart Disease in Individuals with Diabetes and Prediabetes: A Prospective Study in the UK Biobank.Nutrients. 2023 Jul 17;15(14):3176. doi: 10.3390/nu15143176. Nutrients. 2023. PMID: 37513593 Free PMC article.
-
Classes of Lipid Mediators and Their Effects on Vascular Inflammation in Atherosclerosis.Int J Mol Sci. 2023 Jan 13;24(2):1637. doi: 10.3390/ijms24021637. Int J Mol Sci. 2023. PMID: 36675152 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials